AU2163501A - Method for producing epinastine hydrochloride in the high-melting crystal modification - Google Patents

Method for producing epinastine hydrochloride in the high-melting crystal modification

Info

Publication number
AU2163501A
AU2163501A AU21635/01A AU2163501A AU2163501A AU 2163501 A AU2163501 A AU 2163501A AU 21635/01 A AU21635/01 A AU 21635/01A AU 2163501 A AU2163501 A AU 2163501A AU 2163501 A AU2163501 A AU 2163501A
Authority
AU
Australia
Prior art keywords
epinastine hydrochloride
crystal modification
product
epinastine
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21635/01A
Other languages
English (en)
Inventor
Rolf Dach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU2163501A publication Critical patent/AU2163501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU21635/01A 1999-12-03 2000-11-29 Method for producing epinastine hydrochloride in the high-melting crystal modification Abandoned AU2163501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19958460 1999-12-03
DE19958460A DE19958460A1 (de) 1999-12-03 1999-12-03 Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
PCT/EP2000/011942 WO2001040229A2 (de) 1999-12-03 2000-11-29 Verfahren zur herstellung von epinastine-hydrochlorid in der hochschmelzenden kristallmodifikation

Publications (1)

Publication Number Publication Date
AU2163501A true AU2163501A (en) 2001-06-12

Family

ID=7931396

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21635/01A Abandoned AU2163501A (en) 1999-12-03 2000-11-29 Method for producing epinastine hydrochloride in the high-melting crystal modification

Country Status (23)

Country Link
US (1) US6403790B1 (enExample)
EP (1) EP1237892B1 (enExample)
JP (1) JP4789383B2 (enExample)
KR (1) KR100737191B1 (enExample)
CN (1) CN1402728A (enExample)
AR (1) AR026678A1 (enExample)
AT (1) ATE238306T1 (enExample)
AU (1) AU2163501A (enExample)
BR (1) BR0016052A (enExample)
CA (1) CA2389170C (enExample)
CO (1) CO5251470A1 (enExample)
CZ (1) CZ20021843A3 (enExample)
DE (2) DE19958460A1 (enExample)
DK (1) DK1237892T3 (enExample)
EA (1) EA200200630A1 (enExample)
ES (1) ES2198368T3 (enExample)
HU (1) HUP0203501A2 (enExample)
IL (1) IL149711A0 (enExample)
MX (1) MXPA02005330A (enExample)
PL (1) PL355628A1 (enExample)
PT (1) PT1237892E (enExample)
UY (1) UY26461A1 (enExample)
WO (1) WO2001040229A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
MXPA05000071A (es) * 2002-08-02 2005-04-08 Boehringer Ingelheim Int Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas.
KR101386530B1 (ko) 2006-12-29 2014-04-18 케이피엑스 라이프사이언스 주식회사 순도 및 수율이 향상된3-아미노-9,13ｂ디하이드로-1Ｈ-디벤즈-[ｃ,ｆ]이미다조[1,5-ａ]-아제핀 염산염의 제조방법
CN104098575B (zh) * 2013-04-15 2016-06-01 四川科瑞德凯华制药有限公司 一种盐酸依匹斯汀晶型及其制备方法和用途
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
DE4102148A1 (de) * 1991-01-25 1992-07-30 Boehringer Ingelheim Kg Verfahren zur herstellung von 3-amino-9,13b-dihydro-1h-dibenz-(c,f)imidazol(1,5-a)azepin-hydrochlorid
JP3726291B2 (ja) * 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
JPH083160A (ja) * 1994-06-22 1996-01-09 Nippon Kayaku Co Ltd ６−（１−ｈ−イミダゾール−１−イル）−７−ニトロ−２，３−（１ｈ，４ｈ）−キノキサリンジオン塩酸塩又は硫酸塩の分離精製法
JP3755908B2 (ja) * 1994-08-17 2006-03-15 塩野義製薬株式会社 セファロスポリン化合物の晶析法
JPH0948765A (ja) * 1995-08-04 1997-02-18 Toyama Chem Co Ltd 安定な結晶構造を有するトリアゾール誘導体およびその製造法
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne

Also Published As

Publication number Publication date
EP1237892A2 (de) 2002-09-11
CO5251470A1 (es) 2003-02-28
ES2198368T3 (es) 2004-02-01
EP1237892B1 (de) 2003-04-23
AR026678A1 (es) 2003-02-19
DK1237892T3 (da) 2003-08-04
CN1402728A (zh) 2003-03-12
JP4789383B2 (ja) 2011-10-12
UY26461A1 (es) 2001-07-31
WO2001040229A3 (de) 2001-12-06
KR20020058080A (ko) 2002-07-12
DE19958460A1 (de) 2001-06-07
KR100737191B1 (ko) 2007-07-10
CA2389170A1 (en) 2001-06-07
ATE238306T1 (de) 2003-05-15
JP2003515536A (ja) 2003-05-07
PT1237892E (pt) 2003-08-29
CA2389170C (en) 2008-01-08
CZ20021843A3 (cs) 2002-08-14
IL149711A0 (en) 2002-11-10
PL355628A1 (en) 2004-05-04
BR0016052A (pt) 2002-07-23
EA200200630A1 (ru) 2002-12-26
HUP0203501A2 (hu) 2003-03-28
US6403790B1 (en) 2002-06-11
MXPA02005330A (es) 2003-01-28
WO2001040229A2 (de) 2001-06-07
DE50001920D1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
KR20000019206A (ko) 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
US5847118A (en) Methods for the manufacture of amorphous cefuroxime axetil
CA2389170C (en) A process for the production of epinastine hydrochloride in the high-melting crystal modification
US4786735A (en) Process for preparing cimetidine polymorph B
CN118388507A (zh) 一种卢比替定的晶型及其制备方法
EP1435359A1 (en) A process for the purification of roxithromycin
EP2414378B1 (en) Separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid
EA008055B1 (ru) Кристаллические формы оланзапина и способы их получения
GB2395482A (en) Process for preparing non-hygroscopic azithromycin dihydrate
US12391704B2 (en) Method for synthesizing decursin derivative
JPH03240793A (ja) アンフォテリシンｂの精製方法および組成物
KR101485418B1 (ko) 고순도 미르타자핀의 제조방법
EP1363894A1 (en) Preparation of warfarin sodium from warfarin acid
CA2367903A1 (en) Novel method for producing doxazosin mesylate in a crystalline modification designated as form a
AU2007316607B2 (en) Amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl-N-methyl-acetamide
CN109970736A (zh) 一种他达拉非结晶方法
AU713086B2 (en) 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta, 20-epoxy-1- hydroxy-9-oxo-19-norcyclopropa(g)tax-11-en-13alpha-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3- phenylpropionate dihydrate and its process of preparation
HU194893B (en) Process for producing cristalline sodium salt of d-6-brace alpha-(/2-oxo-3-furfuriliden-amino-imidazolidin-1-yl/-carbonyl-amino)-thienyl-2-acetamido-brace closed-penicillanic acid and pharmaceutical compositions containing them
US4370485A (en) Germaazaspirodiones
HU181483B (hu) Eljárás ( + )-apovinkaminsav-etilészter tisztítására
HK1130789B (en) Amorphous form of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl-n-methyl-acetamide
AU2002231294A1 (en) Preparation of warfarin sodium warfarin acid

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period